Table 2.
Studies in which DNA repair assays have been used to evaluate human inter-individual and/or tumor-specific variability in DRC. Publications are categorized by DNA repair pathway studied and the type of assay used. Black corresponds to studies in which a single repair pathway was assayed. Blue corresponds to studies in which two or more pathways were assayed as a consequence of a lesion being repaired by more than one pathway or a protein being involved in more than one pathway. Red corresponds to studies in which two or more pathways were assayed simultaneously either through sequencing of two or more genes or by the use of separate repair measurements.
| Repair pathway | Evidence of inter-individual/tumor differences in DRC | |||||||
|---|---|---|---|---|---|---|---|---|
|
Indirect measurements
|
Mutagen Sensitivity |
Direct measurements
|
||||||
| SNP/GWAS | Gene Methylation | mRNA | Protein | Cell free extract | Comet | HCR | ||
| DR | (32) (229) (20) (216) |
(54) (55) (56) (57) (43) (58) |
(48) (230) (231) (58) |
(231) | (64) (66) (48) (42) (231) (131) (7) (52) (53) |
(59) (90) (229) |
||
| MMR | (232) (233) (20) (180) |
(232) (63) (233) |
(230) (57) |
(63) (191) |
(63) (234) (235) |
|||
| NER | (236) (237) (25) (26) (120) (28) (20) (29) (30) (31) |
(70) (72) | (238) (239) (70) (230) (72) |
(240) (70) (72) |
(96) (241) | (106) (128) (238) (110) (242) (107) (131) (243) (108) (120) (129) (118) (121) (7) |
||
| HR | (237) (20) | (244) (66) (69) (245) |
(66) (69) (230) |
(69) | (89) | (98) (99) (101) (237) (97) |
||
| BER & SSBR | (246) (237) (42) (82) (20) |
(68) (71) | (78) (48) (68) (230) (42) (71) (126) |
(71) | (79) (246) (78) (247) (82) (91) (142) (92) (143) |
(237) (96) (100) |
(131) (126) | |
| NHEJ | (237) (248) (20) (180) |
(69) | (69) (230) |
(69) | (87) | (98) (99) (101) (237) (97) |
(243) (122) | |
| FANC | (67) (249) | (244) (64) (65) (66) (245) |
(65) (66) | (64) (67) |
(88) | (128) (129) (7) |
||